Abstract
Patients with diabetes mellitus (DM) have a high prevalence of coronary artery disease (CAD), as diabetes is implicated in the formation of atherosclerotic plaque. Endothelial dysfunction is one of the precursor key steps in the development of atherosclerosis in diabetic subjects. Decreased nitric oxide (NO) production, increased oxidative stress and impaired function of endothelial progenitor cells are the main mechanisms involved in the accelerated atherosclerotic process observed in type 2 DM patients. Therapeutic approaches including classic agents such as statins, angiotensinconverting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), antioxidants and novel agents such as tetrahydrobiopterin (BH4), asymmetric dimethylarginine (ADMA) and homocysteine (tHcy), have been implicated in order to ameliorate endothelial function of diabetic patients.
Keywords: Diabetes mellitus, endothelial dysfunction, oxidative stress, atherosclerosis, endothelium, therapeutic implications, coronary artery disease, statins, antioxidants, obesity
Current Vascular Pharmacology
Title: Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Volume: 10 Issue: 1
Author(s): Dimitris Tousoulis, Anna-Maria Kampoli and Christodoulos Stefanadis
Affiliation:
Keywords: Diabetes mellitus, endothelial dysfunction, oxidative stress, atherosclerosis, endothelium, therapeutic implications, coronary artery disease, statins, antioxidants, obesity
Abstract: Patients with diabetes mellitus (DM) have a high prevalence of coronary artery disease (CAD), as diabetes is implicated in the formation of atherosclerotic plaque. Endothelial dysfunction is one of the precursor key steps in the development of atherosclerosis in diabetic subjects. Decreased nitric oxide (NO) production, increased oxidative stress and impaired function of endothelial progenitor cells are the main mechanisms involved in the accelerated atherosclerotic process observed in type 2 DM patients. Therapeutic approaches including classic agents such as statins, angiotensinconverting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), antioxidants and novel agents such as tetrahydrobiopterin (BH4), asymmetric dimethylarginine (ADMA) and homocysteine (tHcy), have been implicated in order to ameliorate endothelial function of diabetic patients.
Export Options
About this article
Cite this article as:
Tousoulis Dimitris, Kampoli Anna-Maria and Stefanadis Christodoulos, Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives, Current Vascular Pharmacology 2012; 10 (1) . https://dx.doi.org/10.2174/157016112798829797
DOI https://dx.doi.org/10.2174/157016112798829797 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus
Current Drug Targets Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Rhinocerebral Mucormycosis with Orosinusal Involvement: Diagnostic and Surgical Treatment Guidelines
Endocrine, Metabolic & Immune Disorders - Drug Targets DNA Vaccines: A Mini Review
Recent Patents on DNA & Gene Sequences Advanced Glycation: A Novel Outlook on Atherosclerosis
Current Pharmaceutical Design Renin Angiotensin System and Cytokines in Chronic Kidney Disease: Clinical and Experimental Evidence
Protein & Peptide Letters Measurement and Mapping of Retinal Leakage and Retinal Thickness - Surrogate Outcomes for the Initial Stages of Diabetic Retinopathy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents All for Statins and Statins for All; An Update
Current Pharmaceutical Design Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
Endocrine, Metabolic & Immune Disorders - Drug Targets Demographic and Clinical Evaluation of Patients with Pancreatic Cancer in Mashhad University of Medical Sciences During 2002-2013
Current Cancer Therapy Reviews Differential Contribution of Clinical Amounts of Acetaldehyde to Skeletal and Cardiac Muscle Dysfunction in Alcoholic Myopathy
Current Pharmaceutical Design Progress in the Research on Naturally Occurring Flavones and Flavonols: An Overview
Current Organic Chemistry VEGF in the Muscular Layer of Placental Blood Vessels: Immuno- Expression in Preeclampsia and Intrauterine Growth Restrictrion and its Association with the Antioxidant Status
Cardiovascular & Hematological Agents in Medicinal Chemistry Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Is Intake of Flavonoid-Based Food Supplements During Pregnancy Safe for the Developing Child? A Literature Review
Current Drug Targets Preface
Current Molecular Medicine Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives
Mini-Reviews in Medicinal Chemistry Patent Selections:
Recent Patents on Biomarkers Antidiabetic Potential of Fabaceae Family: An Overview
Current Nutrition & Food Science Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets